For Investors

Investment Thesis: The 10x Transformation

We are not just building a tool; we are building the infrastructure for a data-driven healthcare future. Our platform decouples clinical revenue from manual labor, transforming high-latency medical services into high-margin software outputs.

Current Vertical: Sleep Diagnostic Scoring (Automated PSG Analysis).

The Delta: Reducing manual scoring from 2-4 hours to under 5 minutes.

Infrastructure: SOC 2 Type II compliant, cloud-native backbone via Nuvollo.

Validation: Strategic partnership with MedSleep Inc. for clinical scaling.

Phase 1: The Sleep "Wedge" (Current)

Phase 2: Cardiac Ultrasound (Months 18–24)

Headline: Market Entry & In-Lab Dominance
Focus: Automated Sleep Staging and HSAT (Home Sleep Apnea Testing).
Goal: Capture 15% of the North American market by 2028.
Moat: 95%+ accuracy validated by strategic partner MedSleep Inc.

Phase 2: Cardiac Ultrasound (Months 18–24)

Headline: Strategic Vertical Expansion
Focus: Deployment of the Aegis engine into Echocardiography.
Leverage: Utilizing Proprietary Signal Transferability to analyze cardiac rhythms and ultrasound data.
Value: Dramatically reducing diagnostic time in the $20B+ cardiology market.

Phase 3: Broad Diagnostic OS (24+ Months)

Phase 2: Cardiac Ultrasound (Months 18–24)

Phase 3: Broad Diagnostic OS (24+ Months)

Headline: The Universal Diagnostic Platform
Focus: Expansion into Respiratory and Neurological biosignal analysis.
Goal: Becoming the default operating system for all medical diagnostic software outputs globally.

24-Month Strategic Milestones

We are deploying Series A capital to transition from a validated "Wedge" in sleep diagnostics to a multi-vertical healthcare platform.

Commercial Scaling: Expanding our North American footprint to capture 15% of the independent sleep lab market.

Vertical Expansion: Deployment of the Aegis "Signals-to-Insight" engine into Echocardiography (Cardiac Ultrasound) and broader biosignal diagnostics.

Institutional Maturity: Finalizing regulatory certifications and Phase II clinical trials to ensure seamless global market entry.

Regulatory Roadmap: The Path to Global Clearance

Phase 1: Infrastructure & Quality Systems (Months 0–6)

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Phase 2: Clinical Validation & Peer Review (Months 6–12)

Focus: Building the Institutional Backbone

ISO 13485:2016 Certificatio
SOC 2 Type II Finalization
IEC 62304 Compliance

Phase 2: Clinical Validation & Peer Review (Months 6–12)

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Phase 2: Clinical Validation & Peer Review (Months 6–12)

Focus: Strengthening the "Gold Standard" Proof

MedSleep Pilot Expansion
Peer-Reviewed Publication
Pivotal Study Initiation

Phase 3: Market Authorization & Clearance (Months 12–18)

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Focus: Achieving Formal Market Entry

FDA 510(k) Submission (USA)
Health Canada Class II License
HIPAA / GDPR Audit

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Focus: Transitioning to a Multi-Vertical Platform

CE Mark (MDR) Submission
Cardiac Ultrasound (Echocardiography) Pilot
Post-Market Surveillance

Scale Architects: De-risking Clinical Commercialization

Frank Cally A. Tabuco | Chief Data Scientist

The Model-Accuracy Engine

Clinical Mastery: Peer-reviewed specialist with 95%+ accuracy in high-stakes clinical AI and image analysis.
The "First Principles" Lead: Architecting the transition to Transformer-based models to capture complex, multi-channel biosignals.
Regulatory Rigour: Expert in managing inter-rater variability and label noise to ensure scoring is defensible for FDA and Health Canada.

Lester Kim Lagrimas | Chief Engineer

The Productionization Backbone

Industrial Scale: Specialized in turning research models into secure, national-scale production services with real-time sensor fusion.
Institutional Trust: Architecting security-minded pipelines with strict audit trails and QC pathways for HIPAA and PHIPA compliance.
System Interoperability: Ensuring seamless EMR integration via HL7/FHIR standards to drive widespread hospital adoption.

Audit, Ethics, and Governance Committee

Joey Bermudez | Chairman of the Board of Directors | Independent Director

Banking Authority: A 40-year veteran of high-stakes finance and corporate strategy defined by transparency and integrity.
Executive Leadership: Former President and CEO of Chinatrust (Philippines) and Philippine Veterans Bank.
Peer Among Giants: Served as the 60th President of the Management Association of the Philippines (MAP), leading an elite body of 850 CEOs and COOs.
Strategic Oversight: Formalized as a Strategic Advisor in March 2026 to guide Series A scaling and roadmap development.
Academic Foundation: Former educator in Strategic Management for graduate programs collaborating with IESE Business School.

Alberto Turri | FNS LLC | Independent Director

Swiss Precision: A veteran of the Swiss financial sector with a career rooted in the rigorous standards of Lugano-based governance.
International Connectivity: Currently leads initiatives at Foundry Network Services (Dubai), bridging North American innovation with global capital markets.
· Fiduciary Responsibility: Extensive experience managing complex corporate structures while maintaining the highest levels of transparency.
Institutional Guardrail: Mandated to provide strategic oversight on the company's Series A scaling and long-term roadmap.
Active Stewardship: Engaged in quarterly governance reviews and mandatory strategy summits to ensure alignment with global best practices.

Dr. Timothy Damaso | Physiomed | Independent Director

Independent Director & Aegis Anchor: Serves as the cornerstone for clinical integrity, anchoring technological innovation in the bedrock of evidence-based governance.
Ethics & Data Sovereignty: Leads the oversight of clinical data sovereignty and bioethics, ensuring all corporate partnerships adhere to the highest standards of medical ethics.
Governance & Accuracy: Provides the essential oversight required to validate AI-driven scoring, specifically monitoring the 95.39% accuracy threshold to protect the integrity of the "Diagnostic Operating System".
Strategic Regulatory Alignment: Oversees the clinical validation protocols essential for the company’s Series A scaling and international regulatory approval.

Regulatory Fast-Track

Objective: Finalizing the FDA 510(k) and Health Canada submission package.

Impact: Transitions Aegis from "software" to a legally cleared "Gold Standard" medical device.

Clinical Integrity

Regulatory Fast-Track

Objective: Executing independent, multi-center validation to verify our 84.5% accuracy beyond MedSleep.

Impact: Proves the "Signal-Agnostic" engine maintains high-fidelity results across diverse hardware.

Commercial Proof

Regulatory Fast-Track

Commercial Proof

Objective: Securing the first 5–10 paying clinic contracts to prove our 80%+ gross margin model.

Impact: Converts the pilot waitlist into recurring revenue, de-risking the Series A commercial roadmap.

Engineering Hub ($1.08M)

Regulatory & Clinical ($1.29M)

Infrastructure ($480,000)

Objective: Onshoring four senior specialists in Toronto to augment our Scale Architects in hardening the "Physician Co-Pilot" infrastructure.
Impact: Guarantees 99.9% operational uptime across all enterprise clinical deployments, transforming the platform into production-grade infrastructure.

Infrastructure ($480,000)

Regulatory & Clinical ($1.29M)

Infrastructure ($480,000)

Objective: Scaling GPU density and cloud inference engines to drop per-study costs to near-zero.
Impact: Decouples clinical revenue from manual labor, securing the company’s 80%+ gross margin target as it scales.

Regulatory & Clinical ($1.29M)

Objective: Finalizing formal FDA 510(k) and Health Canada market authorization for the Diagnostic OS.
Impact: Establishes the legally cleared "Gold Standard" moat required for national-scale deployment and institutional adoption.

Institutional Trust & Compliance

Data Sovereignty

Institutional Oversight

Verified Accuracy

Ascend Aegis ensures total data sovereignty through full compliance with global healthcare standards. Our Nuvollo-powered infrastructure provides mission-critical security and jurisdictional integrity, de-risking international expansion. This foundation offers a secure, scalable architecture engineered for high-fidelity, worldwide diagnostic deployment.

Verified Accuracy

Institutional Oversight

Verified Accuracy

Aegis delivers a consistent 84.5% agreement with human-scored gold standards, eliminating subjective manual variability. This verified accuracy, backed by explainable AI transparency, builds institutional trust. We provide the high-fidelity precision necessary to standardize clinical outcomes and scale diagnostic automation globally.

Institutional Oversight

Led by Dr. Stephen Glazer, our regular clinical validation sessions ensure the highest standards of integrity. By bridging AI performance with expert medical oversight, we provide transparent, high-fidelity results. This integrity-driven leadership de-risks deployment and builds lasting institutional trust.

Care, Standardized.

The Signal-Agnostic Diagnostic Operating System

Investment Thesis: The 10x Transformation

Phase 1: The Sleep "Wedge" (Current)

Phase 2: Cardiac Ultrasound (Months 18–24)

Phase 2: Cardiac Ultrasound (Months 18–24)

Phase 2: Cardiac Ultrasound (Months 18–24)

Phase 2: Cardiac Ultrasound (Months 18–24)

Phase 2: Cardiac Ultrasound (Months 18–24)

Phase 3: Broad Diagnostic OS (24+ Months)

Phase 2: Cardiac Ultrasound (Months 18–24)

Phase 3: Broad Diagnostic OS (24+ Months)

24-Month Strategic Milestones

Regulatory Roadmap: The Path to Global Clearance

Phase 1: Infrastructure & Quality Systems (Months 0–6)

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Phase 2: Clinical Validation & Peer Review (Months 6–12)

Phase 2: Clinical Validation & Peer Review (Months 6–12)

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Phase 2: Clinical Validation & Peer Review (Months 6–12)

Phase 3: Market Authorization & Clearance (Months 12–18)

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Phase 4: Vertical Expansion & Global Scaling (Months 18–24+)

Scale Architects: De-risking Clinical Commercialization

Frank Cally A. Tabuco | Chief Data Scientist

Lester Kim Lagrimas | Chief Engineer

Audit, Ethics, and Governance Committee

Joey Bermudez | Chairman of the Board of Directors | Independent Director

Alberto Turri | FNS LLC | Independent Director

Dr. Timothy Damaso | Physiomed | Independent Director

Current Strategic Focus: The De-risking Funding ($300k)

Regulatory Fast-Track

Regulatory Fast-Track

Regulatory Fast-Track

Clinical Integrity

Regulatory Fast-Track

Regulatory Fast-Track

Commercial Proof

Regulatory Fast-Track

Commercial Proof

Strategic Roadmap: Series A Capital Deployment ($2.85M)

Engineering Hub ($1.08M)

Regulatory & Clinical ($1.29M)

Infrastructure ($480,000)

Infrastructure ($480,000)

Regulatory & Clinical ($1.29M)

Infrastructure ($480,000)

Regulatory & Clinical ($1.29M)

Regulatory & Clinical ($1.29M)

Regulatory & Clinical ($1.29M)

Institutional Trust & Compliance

Data Sovereignty

Institutional Oversight

Verified Accuracy

Verified Accuracy

Institutional Oversight

Verified Accuracy

Institutional Oversight

Institutional Oversight

Institutional Oversight

Access the Data Room

Investor Contact & Inquiries

If you are interested in joining our Series A round or learning more about our strategic vision, please contact our executive office.

Primary Contact: Brianna Morissette - Chief of Staff

This website uses cookies.